Targeted Therapy to Inhibit Connective Tissue Growth in Pancreatic Cancer
Researchers are testing a new antibody, a type of targeted therapy, in combination with standard treatment for pancreatic cancer in a phase III trial.
Comparing Two Types of Radiotherapy for Pancreatic Tumors that Cannot Be Surgically Removed
Researchers are comparing standard radiotherapy treatment with a newer type of radiation that uses heavy ions, for nonsurgical pancreatic cancer patients.
Questions to Ask Before You Begin Chemotherapy
Do you want to better understand your pancreatic cancer treatment? Dr. Andrew Hendifar outlines important questions to ask before starting chemotherapy.
Testing a New Drug to Attack Pancreatic Tumor Blood Vessels
A clinical trial is testing a new drug combination that damages the tumor blood vessels and allows chemotherapy drugs to enter the tumor.
Electric Fields to Enhance Pancreatic Cancer Chemotherapy
A clinical trial uses electric fields to help slow the growth of tumor cells, In a clinical trial for pancreatic cancer patients.
Targeting AXL May Improve Chemotherapy for Pancreatic Cancer
Dr. Shaalan Beg describes a clinical trial using the kinase inhibitor bemcentinib along with chemotherapy as a way to slow down or stop pancreatic cancer.
Radiotherapy Implant plus Standard Chemotherapy
The OncoSil radiotherapy implant device is being tested on pancreatic cancer in a clinical trial that combines it with standard chemotherapy.
A New Combination Chemotherapy Before Surgery
A new clinical trial adds vitamin D to standard of care chemotherapy before surgery, to make pancreatic cancer tumors more removable.
Testing the Effectiveness of Immunotherapy Added to a New Drug Combination
Researchers are testing a drug combination that adds immunotherapy to standard drugs used to treat pancreatic cancer and an antimalarial drug.
Testing Immunotherapy for Safety Before and After Pancreatic Cancer Removal
Researchers are testing a new monoclonal antibody to see if it helps patients with pancreatic tumors that can be surgically removed.
Collaborative Multi-Center Immunotherapy Trial Targets CD40 and PD-1
Dr. Mark O’Hara outlines a collaborative clinical trial of two immunotherapy agents–a checkpoint inhibitor and a monoclonal antibody–plus standard chemotherapy.